CPS: Clinical Prognostic Score to Predict Relapse in VL
Study Details
Study Description
Brief Summary
This prospective cohort study has the aim to develop a prognostic tool to predict relapse in patients suffering from visceral leishmaniasis (VL) from VL endemic regions in Ethiopia.
Therefore, comprehensive clinical and laboratory characterization of all confirmed VL patients before and during treatment will be performed in order to identify the factors that determine prognosis of the patients. This approach would result in more efficient patient care and would reduce the case fatality and morbidity, and improve follow-up and care for those at risk of VL relapse.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Certain patient groups seem to be at higher risk of poor outcomes. Although the average case fatality rate was <10% in Ethiopia , certain subgroups of VL patients are at significantly higher risk of dying, with case fatality rates as high as 39% when patients coinfected with HIV or sepsis. The host's immunocompetence appears to play a critical factor associated with disease development, severity, treatment success and disease relapse. Yet, a substantial group of immunocompetent patients also fail to respond well to treatment, or develop relapse after cure. Relapse is increasingly recognized as an important clinical challenge, with 10-15% estimated to develop relapse in the Ethiopian setting. Understanding which factors determine prognosis among VL patients is key in improving outcomes, as high-risk patients can be identified and receive additional monitoring, care, investigations or preferential treatment with safer or more effective drugs.
One of the strategies to improve patient outcome is identification of factors that determine the prognosis of a patient. These factors can be used in clinical decision tools to provide the most appropriate care for each patient. With the key prognostic factors, patients can be stratified in high and low risk of relapse, treatment failure and mortality and can be treated accordingly, providing intensive monitoring and/or treatment of comorbidities of high-risk patients and a more decentralized follow-up for low-risk patients. This approach would result in more efficient patient care and would reduce the case fatality and morbidity, and improve follow-up and care for those at risk of VL relapse.
No clinical tools for prediction of relapse and treatment failure currently exist. The existing clinical tools for predicting mortality developed so far have a fair accuracy but these tools could further be improved by using prognostic markers both before and during treatment and including more relevant parameters which were previously ignored, such as more laboratory parameters including coagulation profile, blood culture, immunological markers and more relevant clinical parameters such as sepsis and comorbidities.
This study will perform a comprehensive clinical and laboratory characterization of all confirmed VL patients before and during treatment with the main objective to develop a prognostic tool for unfavorable outcome among hospitalized patients. It is planned to develop tools of different complexity, geared towards the capacity of the health facility and also study the added effect of each variable in the tool. The data from this study will address a number of outstanding unanswered questions that could help to improve or standardize VL management.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| VL patients VL infected individuals residing in/ with travel history to VL-endemic areas in Northern Ethiopia |
Other: No intervention
No intervention
|
Outcome Measures
Primary Outcome Measures
- Identification of risk factors for relapse [December 2026]
The association between development of relapse and potential risk factors (demographic/clinical characteristics as well as host immunity/Leishmania infection markers)
- Prognostic tool for relapse [December 2026]
A clinical decision algorithm, prioritizing and integrating identified risk factors, that is able to most efficiently predict the risk of developing relapse within 12 months after start of treatment
Secondary Outcome Measures
- Patterns in host immune markers for VL relapse, treatment failure and death [December 2026]
The association between the risk of VL relapse/ treatment failure/ death and the levels and evolution of the different host immune markers.
- Identification of risk factors for treatment failure [December 2026]
The association between the occurence of treatment failure and potential risk factors (demographic/clinical characteristics as well as host immunity/Leishmania infection markers)
- Identification of risk factors for death [December 2026]
The association between occurrence of death and potential risk factors (demographic/clinical characteristics as well as host immunity/Leishmania infection markers)
Eligibility Criteria
Criteria
Inclusion Criteria:
- clinically or parasitologically confirmed VL
Exclusion Criteria:
-
Age under 12 years
-
VL patients already on treatment for 3 days or more
-
Severe critical condition or other circumstances that make the study medically inadvisable
-
Unlikely to adhere to follow up visits during the study period (e.g. patients who live or work very far away) AND not reachable by phone for follow-up information
-
Pregnant or lactating woman
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Institute of Tropical Medicine, Belgium
- University of Gondar
Investigators
- Study Chair: Annelies Mondelaers, PhD, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
- Principal Investigator: Eleni Ayele, MD, University of Gondar, Gondar, Ethiopia
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1544/21